Limitations of performance status assessment in elderly with acute myeloid leukemia  by Carbonell, Ana Lúcia Ippolito & de Lourdes Chauffaille, Maria
CL
e
A
U
a
A
R
A
A
I
E
T
c
s
o
u
w
e
s
s
(
h
m
a
i
u
p
h
1
rrev bras hematol hemoter. 2 0 1 5;3  7(4):259–262
www.rbhh.org
Revista Brasileira de Hematologia e Hemoterapia
Brazilian Journal of Hematology and Hemotherapy
ase Report
imitations  of  performance  status  assessment  in
lderly with  acute  myeloid  leukemia
na Lúcia Ippolito Carbonell ∗, Maria de Lourdes Chauffaille
niversidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil
 r  t  i  c  l  e  i  n  f  o
rticle history:eceived 23 October 2014
ccepted 25 December 2014
vailable online 14 April 2015
and  functional  statusntroduction
lderly patients present clinical and functional heterogeneity.
hus the chronological age (60 years and older) alone does not
haracterize this group of individuals correctly. Performance
tatus scales such as the Karnofsky Performance Scale (KPS)1
r Eastern Cooperative Oncologic Group Scale (ECOG),2 are
sed by hematologists in decision making for elderly patients
ith cancer. Good performance status is deﬁned as a KPS
qual to or greater than 80% or an ECOG less than 2. These
cores are one of the criteria utilized to choose the treatment
trategy for elderly patients with acute myeloid leukemia
AML). AML  is more  frequent in the aged. Considering the
igh risk of toxicity during AML  treatment in elderly patients,
any researchers have recommended the application of geri-
tric instruments at baseline and in the follow up of these
ndividuals. The objective of this paper is to improve the
nderstanding of how geriatric approaches may beneﬁt the
erformance status assessment of elderly patients with AML.
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eserved.Two cases, as clinical challenges, are used to exemplify this
clinical context.
Clinical  challenges
Case 1 – Patient 1: 75-year-old man  with de novo AML, normal
karyotype, KPS of 90% and ECOG of 1
Case 2 – Patient 2: 65-year-old woman with de novo AML,
normal karyotype, KPS of 80% and ECOG of 1
Question: How do geriatric instruments improve the char-
acterization of these patients? (Table 1).
Brief  considerations  about  performance  status, SP, Brazil.
Performance status – assessed by KPS and/or by ECOG (Table 2)
– is the traditional method applied by hematologists to
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Table 1 – Hematologic data of clinical challenge patients.
Patient 1 Patient 2
Age (years) 75 65
Gender Male Female
Diagnosis De novo AML De novo AML
Marrow blasts (%) 38 47
Hemoglobin (g/dL) 10.7 8.9
White blood cell count (×103/L) 3400 2870
Platelet count (×103/L) 92 50
AML: acute myeloid leukemia.
older patients is Comprehensive Geriatric Assessment (CGA).
CGA is a multidisciplinary and time-consuming approachevaluate the disease/treatment impact on the elderly patient’s
ability to care for themselves and to work.
These instruments are not based on a systematic ques-
tionnaire. The scores are obtained based on a general
impression of the clinician about the patient’s symptoms
and the patient’s autonomy to care for themself and to
work. One disadvantage of this method is the lack of deﬁ-
nitions to speciﬁcally characterize the score levels of these
scales.3
Functional status is the level of autonomy that an individ-
ual has in daily activities. The Activity Daily Living Scale (ADL)4
and Instrumental Activity Of Daily Living Scale (IADL)5 are
complementary tools widely validated to measure functional
status.
ADL was validated by Katz in chronically ill patients and is
composed of six questions about speciﬁc and universal tasks.4IADL was delineated by Lawton and is a scale with nine ques-
tions with three possible answers: able, able with help and
Table 2 – Correlations between performance and functional sca
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unable. It refers to the autonomy in activities that are more
inﬂuenced by cultural context (Table 2).
In 1995, Mor  et al.6 evaluated the validity of KPS by showing
the autonomy in daily living activities for each KPS assessed
in 685 patients with advanced cancer on applying the KPS and
ADL. They showed that the autonomy of these patients was
lower as their KPS score decreased.
KPS, ECOG, ADL and IADL refer to the same construct, i.e.,
to the same abstract theoretical concept. Different to KPS and
ECOG, ADL and IADL employ a sequence of speciﬁc questions.
The possible answers to each question are graduated in two
(able or unable) or in three (able, able with help, and unable)
levels. These instruments highlight improvements or impair-
ments in functionality during the follow up of the patient.
As shown in Table 2, the correlation between these scores
suggests that patients with poor KPS have lost their auton-
omy in the IADL5 and are at risk of dependence in basic ADL.4
However, individuals with good KPS probably have preserved
autonomy in the ADL dimension but may evolve with some
IADL dependence.
Loosing autonomy in ADL and having poor scores in KPS
(≤80%) or ECOG (>1) are of prognostic value.3,7
However, despite the prognostic value of performance sta-
tus, elderly patients with good KPS could be at high risk to
succumb during the induction phase of AML  treatment for
reasons not related to the disease. This event has justiﬁed
some researchers to applying geriatric approaches in elderly
patients with AML. The gold standard method for evaluatingthat includes functional, cognitive, psychological status,
comorbidity, nutritional, polypharmacy and social support
les.
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Table 3 – Functional assessment and comorbidity scores
of clinical challenge patients.
Patient 1 Patient 2
Age (years) 75 65
Gender Male Female
KPS/ECOG 90%/1 80%/1
ADL/IADL Independent Dependenta
HCT-CI 0 3b
KPS: Karnofsky performance scale; ECOG: eastern cooperative
oncologic group scale; ADL: activities of daily living scale;
IADL: instrumental activities of daily living scale; Independent:
no dependence in daily activities; HCT-CI: hematopoietic cell
transplantation-comorbidity index.
a Patient 2 needed help to take medications/locomotion and she
had urinary incontinence.
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atinine equal to 2.6 mg/dL.
ssessments. Over the last 20 years, CGA has been applied
n the oncogeriatric ﬁeld and has aggregated important data
or the therapeutic management of this group of individuals.
t is notable that the ADL and IADL are tools widely used for
he functional status assessment included in CGA.8
In 2006, Wedding et al.9 demonstrated the beneﬁt of adding
he IADL to the KPS in the functional assessment of elderly
atients with AML. Since then, several other researchers have
tudied the impact of geriatric parameters in the survival
nd the quality of life of older patients with hematological
alignancies.10
Aging is associated with a high incidence of comorbidities
hat have a signiﬁcant impact on survival and on complica-
ions of treatment.11 Comorbidities are morbid entities that
ave already been diagnosed at the time of the diagnosis of
he index disease, here AML, or that are diagnosed during the
atient follow up.
Extermann et al.11 studied the tools used for comorbid-
ty scoring in elderly patients with cancer. They showed that
omorbidity scores increase with advancing age and that
hese scores are correlated with mortality but not associated
o functional status.11 In conclusion, comorbidity and func-
ionality are independent variables and should be measured
eparately in older patients with cancer.
Recently, hematologists developed disease speciﬁc instru-
ents that measure the impact of comorbidities on elderly
ndividuals with AML, myelodysplastic syndromes and those
ubmitted to hematopoietic stem cell transplantation. Sor-
or et al. developed the Hematopoietic Cell Transplantation
omorbidity Index (HCT-CI)12 which has already been vali-
ated in patients with AML.
What happened to the patient’s assessment with the aggre-
ation of some geriatric scales? Table 3 shows the result of
unctional and comorbidity assessment of the two reported
ases.
linical  challenges  follow-upatient 1 was submitted to the standard treatment with full
oses of the AML  induction protocol and one consolidation 1 5;3  7(4):259–262 261
phase. After consolidation, he evolved with sepsis and pro-
longed neutropenic period. Six months after the diagnosis of
AML, he was alive and without evidence of disease.
Patient 2 was submitted to exclusive palliative care, accord-
ing to her and her family’s wishes and considering the impact
of her comorbidity score and her dependence according to
ADL/IADL. She died of AML  four months after diagnosis.
Considering these two patients, both with good KPS, Patient
1 was ten years older than Patient 2. Despite this, he had
greater autonomy and a lower comorbidity score that delin-
eated a clinical context more  favorable to AML  treatment.
Moreover, the aggregation of geriatric tools added information
about Patient 2 that identiﬁed her functional and comorbidity-
related risks. These instruments provided speciﬁc information
for the management of her ﬁnal phase of life.
In conclusion, ADL and IADL improved the sensitivity of
the functional assessment of these elderly patients. They
added important information about Patient 2 that changed
her performance score from ‘good’ to ‘good but dependent’.
Furthermore, the HCT-CI score predicted the impact of comor-
bidities on her survival. The applications of ADL, IADL and
HCT-CI improve the assessment of elderly patients with hema-
tological malignances.
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